| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
73,545 |
66,975 |
$9.40M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
78,713 |
73,774 |
$7.32M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
29,898 |
26,992 |
$4.02M |
| 80053 |
Comprehensive metabolic panel |
77,441 |
68,165 |
$519K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,788 |
6,518 |
$512K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
3,479 |
1,651 |
$506K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
4,138 |
3,701 |
$483K |
| 0240U |
|
5,344 |
4,691 |
$464K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
27,173 |
22,935 |
$433K |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,128 |
3,644 |
$387K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
80,069 |
69,180 |
$381K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,557 |
1,397 |
$333K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,821 |
3,671 |
$321K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
7,064 |
6,569 |
$295K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
23,669 |
19,248 |
$285K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
2,301 |
1,637 |
$284K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
2,632 |
2,326 |
$283K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
22,843 |
20,421 |
$259K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,049 |
5,444 |
$256K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
8,118 |
5,987 |
$209K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
6,711 |
6,123 |
$209K |
| 77386 |
|
1,243 |
171 |
$192K |
| 36415 |
Collection of venous blood by venipuncture |
89,825 |
74,386 |
$175K |
| 77412 |
|
1,100 |
160 |
$170K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
4,522 |
3,917 |
$162K |
| 81025 |
|
25,599 |
22,957 |
$161K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
8,725 |
6,857 |
$149K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
4,273 |
3,955 |
$137K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
4,211 |
3,935 |
$135K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
1,131 |
557 |
$130K |
| 84484 |
|
17,012 |
13,230 |
$116K |
| 71045 |
Radiologic examination, chest; single view |
8,309 |
7,491 |
$115K |
| 81001 |
|
50,372 |
44,714 |
$104K |
| 77336 |
|
2,016 |
894 |
$98K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
830 |
796 |
$98K |
| G0379 |
Direct admission of patient for hospital observation care |
589 |
459 |
$96K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,840 |
1,444 |
$89K |
| 71046 |
Radiologic examination, chest; 2 views |
4,419 |
4,019 |
$87K |
| 0002A |
|
6,421 |
2,543 |
$81K |
| J3490 |
Unclassified drugs |
29,487 |
16,048 |
$75K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,580 |
1,493 |
$74K |
| 0001A |
|
6,176 |
2,476 |
$70K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
3,318 |
2,856 |
$65K |
| 87088 |
|
8,671 |
7,805 |
$56K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
13,331 |
12,174 |
$55K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,187 |
3,617 |
$55K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,413 |
1,247 |
$50K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,532 |
1,398 |
$43K |
| 80055 |
|
1,604 |
1,521 |
$36K |
| 83690 |
|
6,997 |
6,371 |
$34K |
| G0378 |
Hospital observation service, per hour |
934 |
662 |
$34K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,288 |
3,812 |
$33K |
| 87631 |
|
403 |
377 |
$29K |
| 86803 |
|
2,696 |
2,248 |
$29K |
| 80050 |
General health panel |
660 |
625 |
$26K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,008 |
954 |
$26K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
756 |
697 |
$24K |
| 82677 |
|
1,054 |
1,001 |
$24K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,867 |
1,049 |
$24K |
| 83880 |
|
1,055 |
965 |
$21K |
| 77334 |
|
121 |
82 |
$21K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,911 |
6,878 |
$20K |
| 87400 |
|
3,237 |
1,508 |
$20K |
| 84702 |
|
1,375 |
1,233 |
$20K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
3,339 |
2,795 |
$19K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
84 |
43 |
$19K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
181 |
152 |
$19K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
410 |
314 |
$18K |
| C1714 |
Catheter, transluminal atherectomy, directional |
18 |
12 |
$18K |
| 86780 |
|
1,839 |
1,432 |
$18K |
| 87081 |
|
2,751 |
2,608 |
$17K |
| 82105 |
|
1,103 |
1,049 |
$16K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
858 |
759 |
$16K |
| 86336 |
|
1,055 |
1,000 |
$15K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
353 |
272 |
$15K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
77 |
73 |
$15K |
| 0004A |
|
516 |
368 |
$14K |
| 87449 |
|
1,154 |
1,048 |
$14K |
| 86850 |
|
2,546 |
2,012 |
$14K |
| 85660 |
|
2,670 |
2,244 |
$12K |
| 84439 |
|
1,513 |
1,408 |
$12K |
| 97597 |
|
560 |
309 |
$11K |
| 87340 |
|
1,615 |
1,234 |
$11K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
245 |
214 |
$11K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
513 |
406 |
$10K |
| 86762 |
|
1,086 |
759 |
$10K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
5,754 |
3,336 |
$9K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
156 |
82 |
$9K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
130 |
80 |
$8K |
| 86480 |
|
197 |
174 |
$8K |
| 59025 |
Fetal non-stress test |
142 |
99 |
$7K |
| 85027 |
|
1,412 |
1,238 |
$7K |
| 82077 |
|
823 |
726 |
$7K |
| 77300 |
|
40 |
32 |
$7K |
| 83735 |
|
1,786 |
1,589 |
$7K |
| 86141 |
|
672 |
613 |
$6K |
| 80061 |
Lipid panel |
588 |
558 |
$6K |
| 80320 |
|
815 |
617 |
$6K |
| 82947 |
|
1,505 |
1,389 |
$6K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,071 |
1,898 |
$6K |
| 86900 |
|
2,675 |
2,138 |
$6K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
37 |
37 |
$6K |
| 86901 |
|
2,667 |
2,137 |
$6K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
83 |
64 |
$6K |
| 86039 |
|
772 |
579 |
$5K |
| 37252 |
|
14 |
12 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
810 |
689 |
$5K |
| 85610 |
|
2,351 |
2,022 |
$5K |
| 75710 |
|
22 |
17 |
$5K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
326 |
309 |
$5K |
| 81003 |
|
2,896 |
2,627 |
$4K |
| C1769 |
Guide wire |
484 |
384 |
$4K |
| 99215 |
Prolong outpt/office vis |
78 |
77 |
$4K |
| 87581 |
|
144 |
128 |
$4K |
| 88174 |
|
235 |
221 |
$4K |
| 82950 |
|
994 |
875 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
93 |
86 |
$4K |
| 85018 |
|
1,870 |
1,737 |
$4K |
| 85014 |
|
1,873 |
1,737 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
464 |
451 |
$4K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
83 |
65 |
$3K |
| 77387 |
|
217 |
25 |
$3K |
| 87486 |
|
117 |
104 |
$3K |
| 86235 |
|
100 |
95 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
82 |
74 |
$3K |
| C1753 |
Catheter, intravascular ultrasound |
14 |
14 |
$3K |
| C1760 |
Closure device, vascular (implantable/insertable) |
34 |
27 |
$3K |
| 87420 |
|
202 |
191 |
$3K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
49 |
26 |
$2K |
| 86200 |
|
254 |
240 |
$2K |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
183 |
174 |
$2K |
| 72100 |
|
127 |
112 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
49 |
36 |
$2K |
| 81511 |
|
1,464 |
583 |
$2K |
| 0003A |
|
143 |
62 |
$2K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
29 |
28 |
$2K |
| T2101 |
Human breast milk processing, storage and distribution only |
115 |
15 |
$2K |
| 86431 |
|
535 |
482 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,527 |
1,228 |
$2K |
| 85730 |
|
745 |
625 |
$2K |
| 0071A |
|
90 |
41 |
$2K |
| 83655 |
|
137 |
133 |
$2K |
| 77280 |
|
36 |
25 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,976 |
1,495 |
$2K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
509 |
461 |
$2K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
226 |
204 |
$2K |
| 86738 |
|
107 |
105 |
$2K |
| 86225 |
|
127 |
119 |
$2K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
38 |
36 |
$1K |
| 36902 |
|
27 |
25 |
$1K |
| 87070 |
|
159 |
145 |
$1K |
| 0031A |
|
303 |
134 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
221 |
194 |
$1K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
62 |
59 |
$1K |
| J7050 |
Infusion, normal saline solution, 250 cc |
41 |
39 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,172 |
707 |
$982.11 |
| 0072A |
|
36 |
21 |
$926.79 |
| 87521 |
Neg quan hep c or qual rna |
27 |
27 |
$877.25 |
| A9150 |
Non-prescription drugs |
639 |
495 |
$845.44 |
| 17250 |
|
24 |
13 |
$844.83 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
369 |
294 |
$832.95 |
| 83605 |
|
134 |
96 |
$806.92 |
| 80143 |
|
95 |
77 |
$765.45 |
| 86769 |
|
34 |
25 |
$758.47 |
| 84112 |
|
12 |
12 |
$753.57 |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
170 |
159 |
$698.88 |
| 80179 |
|
74 |
65 |
$672.12 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
221 |
192 |
$619.42 |
| 0034A |
|
16 |
13 |
$589.96 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
12 |
12 |
$564.63 |
| 72040 |
|
28 |
24 |
$549.58 |
| 86140 |
|
150 |
130 |
$507.64 |
| 83970 |
|
14 |
14 |
$495.36 |
| 82550 |
|
128 |
101 |
$481.28 |
| 64483 |
|
84 |
67 |
$446.28 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
26 |
25 |
$425.56 |
| 90715 |
|
12 |
12 |
$403.92 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
13 |
12 |
$340.62 |
| 82553 |
|
48 |
42 |
$335.98 |
| 87077 |
|
51 |
48 |
$310.53 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
12 |
12 |
$306.46 |
| 85651 |
|
77 |
75 |
$286.09 |
| 81222 |
|
605 |
476 |
$285.89 |
| 73564 |
|
15 |
12 |
$272.58 |
| 74019 |
|
12 |
12 |
$249.44 |
| J2704 |
Injection, propofol, 10 mg |
1,475 |
1,127 |
$229.10 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
174 |
115 |
$218.07 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
994 |
592 |
$216.31 |
| 87184 |
|
28 |
25 |
$168.52 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
38 |
32 |
$161.18 |
| 84481 |
|
15 |
14 |
$145.92 |
| 83090 |
|
17 |
17 |
$143.36 |
| 87040 |
|
19 |
12 |
$123.84 |
| 86787 |
|
15 |
12 |
$115.92 |
| 85379 |
|
14 |
14 |
$111.98 |
| 86003 |
|
43 |
40 |
$102.73 |
| 85007 |
|
39 |
37 |
$101.61 |
| 84156 |
|
45 |
36 |
$99.09 |
| 82248 |
|
18 |
14 |
$82.28 |
| 82150 |
|
13 |
12 |
$80.08 |
| 82247 |
|
17 |
14 |
$77.44 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
32 |
24 |
$74.91 |
| J2060 |
Injection, lorazepam, 2 mg |
28 |
27 |
$63.80 |
| J1790 |
Injection, droperidol, up to 5 mg |
15 |
13 |
$61.84 |
| 80047 |
|
23 |
13 |
$58.46 |
| 82570 |
|
21 |
12 |
$56.98 |
| 84100 |
|
13 |
13 |
$56.88 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
27 |
24 |
$49.42 |
| 80076 |
|
22 |
12 |
$48.14 |
| 89240 |
|
73 |
37 |
$42.59 |
| 91300 |
|
5,517 |
4,381 |
$31.67 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
18 |
13 |
$27.93 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
3,245 |
2,765 |
$25.28 |
| 36416 |
|
14 |
13 |
$23.85 |
| 85652 |
|
12 |
12 |
$21.60 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
23 |
13 |
$14.21 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
15 |
14 |
$9.90 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
92 |
86 |
$4.76 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
610 |
458 |
$2.75 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
35 |
25 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
572 |
297 |
$0.00 |
| 11045 |
|
41 |
25 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
247 |
185 |
$0.00 |
| A9270 |
Non-covered item or service |
226 |
128 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
57 |
44 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
17 |
12 |
$0.00 |
| 91305 |
|
12 |
12 |
$0.00 |
| 80329 |
|
54 |
26 |
$0.00 |
| 91303 |
|
43 |
39 |
$0.00 |
| 99152 |
|
423 |
327 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
713 |
273 |
$0.00 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
386 |
342 |
$0.00 |
| 76937 |
|
150 |
120 |
$0.00 |
| J2800 |
Injection, methocarbamol, up to 10 ml |
32 |
25 |
$0.00 |